We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.08 | 0.83% | 131.80 | 131.85 | 130.13 | 130.13 | 4,006,181 | 19:04:06 |
From Apr 2021 to Apr 2024
By Stephen Nakrosis
Merck & Co. Inc. on Tuesday said Health Canada gave conditional approval for Keytruda in combination with chemotherapy to treat certain patients with breast cancer.
The conditional approval was given to treat certain patients with metastatic triple-negative breast cancer who haven't received prior chemotherapy for metastatic disease, the company said.
Health Canada's decision is based on results from the Phase 3 KEYNOTE-355 trial, Merck said. The trial "showed that Keytruda in combination with chemotherapy demonstrated a statistically significant improvement in progression free survival compared to patients treated with placebo in combination with chemotherapy," Merck said.
According to Merck, breast cancer is the second leading cause of death from cancer in Canadian women.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 23, 2021 11:40 ET (16:40 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
